(±) -Nornicotine-d7

(±) -Nornicotine-d7 is the deuterium labeled (±) -Nornicotine (HY-W002112) . (±) -Nornicotine is a major metabolite of Nicotine. (±) -Nornicotine is a partial nAChRs agonist, specifically activating receptor subtypes containing α7 and α6 subunits. (±) -Nornicotine disrupts β-catenin and ZO-1, and induces F-actin depolymerization. (±) -Nornicotine supports self-administration behavior. (±) -Nornicotine can be used in the research of atherosclerosis, Alzheimer's disease, and schizophrenia[1][2][3][4][5].

Product Specifications

Product Name Alternative

Nornicotine-d7

UNSPSC

12352005

Target

Drug Metabolite; Endogenous Metabolite; Isotope-Labeled Compounds; nAChR; β-catenin

Type

Isotope-Labeled Compounds

Related Pathways

Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; Neuronal Signaling; Others; Stem Cell/Wnt

Field of Research

Neurological Disease; Cardiovascular Disease

Solubility

10 mM in DMSO

Smiles

[2H]C1=NC([2H])=C(C([2H])=C1[2H])C2NCCC2([2H])[2H]

Molecular Formula

C9H6D6N2

Molecular Weight

154.24

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Papke RL, et al. The pharmacological activity of nicotine and nornicotine on nAChRs subtypes: relevance to nicotine dependence and drug discovery. J Neurochem. 2007 Apr;101 (1) :160-7. |[3]Gagat M, et al. Nornicotine impairs endothelial cell-cell adherens junction complexes in EA.hy926 cell line via structural reorganization of F-actin. Folia Histochem Cytobiol. 2013;51 (3) :179-92.|[4]Bardo MT, et al. Nornicotine is self-administered intravenously by rats. Psychopharmacology (Berl) . 1999 Oct;146 (3) :290-6.|[5]Hoffman AC, et al. Abuse potential of non-nicotine tobacco smoke components: acetaldehyde, nornicotine, cotinine, and anabasine. Nicotine Tob Res. 2013 Mar;15 (3) :622-32.